Using a machine learning approach to investigate factors associated with treatment-resistant depression among adults with chronic non-cancer pain conditions and major depressive disorder

References

• Friedrich M. Depression is the leading cause of disability around the world. Jama. 2017;317(15):1517.
   Web of Science ®Google Scholar
• Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547.
   PubMed Web of Science ®Google Scholar
• Marcus M, Yasamy T, Ommeren M, et al. Depression: a global public health concern. World Health Organization; 2012. Available from: http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012_pdf. 2014
   Google Scholar
• Khan A, Brown WA. Antidepressants versus placebo in major depression: an overview. World Psychiatry. 2015;14(3):294–300.
   PubMed Web of Science ®Google Scholar
• Kirsch I, Huedo-Medina TB, Pigott HE, et al. Do outcomes of clinical trials resemble those “real world” patients? A reanalysis of the STAR* D antidepressant data set. Psychol Conscious: Theory Res Pract. 2018;5(4):339–345.
   Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. AJP. 2006;163(11):1905–1917.
   Web of Science ®Google Scholar
• Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiatry. 2017;74(1):9–10.
   PubMed Web of Science ®Google Scholar
• Mrazek DA, Hornberger JC, Altar CA, et al. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv. 2014;65(8):977–987.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(8):17.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62:5–9.
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR* D report. AJP. 2006;163(7):1161–1172.
   Google Scholar
• Kubitz N, Mehra M, Potluri RC, et al. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLOS One. 2013;8(10):e76882.
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Reps J, Ryan P. Finding factors that predict treatment‐resistant depression: results of a cohort study. Depress Anxiety. 2018;35(7):668–673.
   PubMed Web of Science ®Google Scholar
• Rizvi SJ, Grima E, Tan M, et al. Treatment-resistant depression in primary care across Canada. Can J Psychiatry. 2014;59(7):349–357.
   PubMed Web of Science ®Google Scholar
• Kapfhammer H-P. Somatic symptoms in depression. Dialogues Clin Neurosci. 2006;8(2):227–239.
   PubMedGoogle Scholar
• Kroenke K, Wu J, Bair MJ, et al. Reciprocal relationship between pain and depression: a 12-month longitudinal analysis in primary care. J Pain. 2011;12(9):964–973.
   PubMed Web of Science ®Google Scholar
• Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163(20):2433–2445.
   PubMed Web of Science ®Google Scholar
• Arola HM, Nicholls E, Mallen C, et al. Self-reported pain interference and symptoms of anxiety and depression in community-dwelling older adults: can a temporal relationship be determined? Eur J Pain. 2010;14(9):966–971.
   PubMed Web of Science ®Google Scholar
• Sheng J, Liu S, Wang Y, et al. The link between depression and chronic pain: neural mechanisms in the brain. Neural Plast. 2017;2017:9724371.
   PubMed Web of Science ®Google Scholar
• Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med. 2004;66(1):17–22.
   PubMed Web of Science ®Google Scholar
• Nie Z, Vairavan S, Narayan VA, et al. Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study. PLOS One. 2018;13(6):e0197268.
   PubMed Web of Science ®Google Scholar
• Balestri M, Calati R, Souery D, et al. Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study. J Affect Disord. 2016;189:224–232.
   PubMed Web of Science ®Google Scholar
• Kautzky A, Dold M, Bartova L, et al. Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatr Scand. 2019;139(1):78–88.
   PubMed Web of Science ®Google Scholar
• Kautzky A, Dold M, Bartova L, et al. Refining prediction in treatment-resistant depression: results of machine learning analyses in the TRD III sample. J Clin Psychiatry. 2018;79(1):16m11385.
   PubMed Web of Science ®Google Scholar
• De Carlo V, Calati R, Serretti A. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: a systematic review. Psychiatry Res. 2016;240:421–430.
   PubMed Web of Science ®Google Scholar
• Bleakley S. Antidepressant drug interactions: evidence and clinical significance. Prog Neurol Psychiatry. 2016;20(3):21–27.
   Web of Science ®Google Scholar
• Qato D, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the united states. JAMA. 2018;319(22):2289–2298.
   PubMed Web of Science ®Google Scholar
• Giummarra MJ, Gibson SJ, Allen AR, et al. Polypharmacy and chronic pain: harm exposure is not all about the opioids. Pain Med. 2015;16(3):472–479.
   PubMed Web of Science ®Google Scholar
• Taylor R Jr, V Pergolizzi J Jr, Puenpatom RA, et al. Economic implications of potential drug-drug interactions in chronic pain patients. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):725–734.
   PubMed Web of Science ®Google Scholar
• PHYTEL. Predictive Modeling and Population Health Management; 2013. Available from: https://app.compendium.com/uploads/user/863cc3c6-3316-459a-a747-3323bd3b6428/4c5909e8-1708-4751-873e-4129cb2ed878/File/86f9d9a5e2f21fb11a5ad8ef2239a76e/1393861691669.pdf.
   Google Scholar
• Perlis RH. A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biol Psychiatry. 2013;74(1):7–14.
   PubMed Web of Science ®Google Scholar
• Collins GS, Mallett S, Omar O, et al. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med. 2011;9(1):103.
   PubMed Web of Science ®Google Scholar
• Goldstein BA, Navar AM, Carter RE. Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. Eur Heart J. 2016;38(23):1805–1814.
   Web of Science ®Google Scholar
• Gail M, Benichou J. Validation studies on a model for breast cancer risk. J Natl Cancer Inst. 1994;86(8):573–575.
   PubMedGoogle Scholar
• Koyner JL, Carey KA, Edelson DP, et al. The development of a machine learning inpatient acute kidney injury prediction model. Crit Care Med. 2018;46(7):1070–1077.
   PubMed Web of Science ®Google Scholar
• Regierer B, Zazzu V, Sudbrak R, et al. Future of medicine: models in predictive diagnostics and personalized medicine. In Molecular diagnostics. Advances in Biochemical Engineering/Biotechnology. Vol. 133. Berlin, Heidelberg: Springer; 2013. p. 15–33. DOI:https://doi.org/10.1007/10_2012_176
   Google Scholar
• Ng K, Ghoting A, Steinhubl SR, et al. PARAMO: a PARAllel predictive MOdeling platform for healthcare analytic research using electronic health records. J Biomed Inform. 2014;48:160–170.
   PubMed Web of Science ®Google Scholar
• Optum. Optum clinformatics data mart [cited 2018 June 7]. Available from: https://www.optum.com/content/dam/optum/resources/productSheets/Clinformatics_for_Data_Mart.pdf. 2018
   Google Scholar
• Schultz J, Joish V. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatr Serv. 2009;60(12):1604–1611.
   PubMed Web of Science ®Google Scholar
• Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(1):1–6.
   PubMed Web of Science ®Google Scholar
• Scherrer JF, Svrakic DM, Freedland KE, et al. Prescription opioid analgesics increase the risk of depression. J Gen Intern Med. 2014;29(3):491–499.
   PubMed Web of Science ®Google Scholar
• Sullivan MD, Edlund MJ, Fan M-Y, et al. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138(2):440–449.
   PubMed Web of Science ®Google Scholar
• Shah A, Hayes CJ, Martin BC. Factors influencing long-term opioid use among opioid naive patients: an examination of initial prescription characteristics and pain etiologies. J Pain. 2017;18(11):1374–1383.
   PubMed Web of Science ®Google Scholar
• Merskey HE. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. Pain. 1986; 3:S1–S226.
   PubMedGoogle Scholar
• Gibson TB, Jing Y, Smith CG, et al. Cost burden of treatment resistance in patients with depression. Am J Managed Care. 2010;16(5):370–377.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Corey-Lisle PK, Marynchenko M, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004;22(6):363–373.
   PubMed Web of Science ®Google Scholar
• Corey-Lisle PK, Birnbaum HG, Greenberg PE, et al. Identification of a claims data" signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry. 2002;63(8):717–726.
   PubMed Web of Science ®Google Scholar
• Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005;25(4):336–341.
   PubMed Web of Science ®Google Scholar
• Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–388.
   PubMed Web of Science ®Google Scholar
• Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156–165.
   PubMed Web of Science ®Google Scholar
• Shmueli G. To explain or to predict? Statist Sci. 2010;25(3):289–310.
   Web of Science ®Google Scholar
• Breiman L. Statistical modeling: the two cultures (with comments and a rejoinder by the author). Statist Sci. 2001;16(3):199–231.
   Web of Science ®Google Scholar
• Khalilia M, Chakraborty S, Popescu M. Predicting disease risks from highly imbalanced data using random forest. BMC Med Inform Decis Mak. 2011;11(1):51.
   PubMed Web of Science ®Google Scholar
• Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2(3):18–22.
   Google Scholar
• Rao SJ. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Taylor & Francis; 2003.
   Google Scholar
• Wilkinson RG, Marmot M. Social determinants of health: the solid facts. Geneva: World Health Organization; 2003.
   Google Scholar
• Tran BX, Ha GH, Vu GT, et al. Indices of change, expectations, and popularity of biological treatments for major depressive disorder between 1988 and 2017: a scientometric analysis. IJERPH. 2019;16(13):2255.
   Web of Science ®Google Scholar
• Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.
   PubMed Web of Science ®Google Scholar
• Saeys Y, Inza I, Larrañaga P. A review of feature selection techniques in bioinformatics. Bioinformatics. 2007;23(19):2507–2517.
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin. 2010;26(10):2475–2484.
   PubMed Web of Science ®Google Scholar
• Scherrer JF, Salas J, Sullivan MD, et al. The influence of prescription opioid use duration and dose on development of treatment resistant depression. Prev Med. 2016;91:110–116.
   PubMed Web of Science ®Google Scholar
• Murphy JA, Sarris J, Byrne GA. Review of the conceptualisation and risk factors associated with treatment-resistant depression. Depress Res Treat. 2017;2017:4176825.
   PubMedGoogle Scholar
• Bennabi D, Aouizerate B, El-Hage W, et al. Risk factors for treatment resistance in unipolar depression: a systematic review. J Affect Disord. 2015;171:137–141.
   PubMed Web of Science ®Google Scholar
• Kautzky A, Baldinger-Melich P, Kranz GS, et al. A new prediction model for evaluating treatment-resistant depression. J Clin Psychiatry. 2017;78(02):215–222.
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder third edition. Am J Psychiatry. 2010;167(10):1.
   PubMed Web of Science ®Google Scholar
• Unützer J, Park M. Strategies to improve the management of depression in primary care. Prim Care. 2012;39(2):415–431.
   PubMed Web of Science ®Google Scholar
• Bair MJ, Wu J, Damush TM, et al. Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med. 2008;70(8):890–897.
   PubMed Web of Science ®Google Scholar
• Cunningham JL, Craner JR, Evans MM, et al. Benzodiazepine use in patients with chronic pain in an interdisciplinary pain rehabilitation program. J Pain Res. 2017;10:311–317.
   PubMed Web of Science ®Google Scholar
• Liu X, Ye W, Watson P, et al. Use of benzodiazepines, hypnotics, and anxiolytics in major depressive disorder: association with chronic pain diseases. J Nerv Ment Dis. 2010;198(8):544–550.
   PubMed Web of Science ®Google Scholar
• van Vliet P, van der Mast RC, van den Broek M, et al. Use of benzodiazepines, depressive symptoms and cognitive function in old age. Int J Geriatr Psychiatry. 2009;24(5):500–508.
   PubMed Web of Science ®Google Scholar
• Howland RH, Wilson MG, Kornstein SG, et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry. 2008;20(4):209–218.
   PubMed Web of Science ®Google Scholar
• Du Vaure CB, Dechartres A, Battin C, et al. Exclusion of patients with concomitant chronic conditions in ongoing randomised controlled trials targeting 10 common chronic conditions and registered at ClinicalTrials.gov: a systematic review of registration details. BMJ Open. 2016;6(9):e012265.
   PubMed Web of Science ®Google Scholar
• Kautzky A, Baldinger P, Souery D, et al. The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. Eur Neuropsychopharmacol. 2015;25(4):441–453.
   PubMed Web of Science ®Google Scholar
• Loo H, Dalery J, Macher J, et al. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin-agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. L'encephale. 2003;29(2):165–171.
   PubMed Web of Science ®Google Scholar
• Pompili M, Serafini G, Innamorati M, et al. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J Biol Psychiatry. 2013;14(6):412–431.
   PubMed Web of Science ®Google Scholar
• Engel-Yeger B, Muzio C, Rinosi G, et al. Extreme sensory processing patterns and their relation with clinical conditions among individuals with major affective disorders. Psychiatry Res. 2016;236:112–118.
   PubMed Web of Science ®Google Scholar
• Tofthagen C. Threats to validity in retrospective studies. J Adv Pract Oncol. 2012;3(3):181–183.
   PubMedGoogle Scholar
• Liu Y, Ho RC-M, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 2012;139(3):230–239.
   PubMed Web of Science ®Google Scholar
• Lu Y, Ho CS, McIntyre RS, et al. Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life Sci. 2018;210:177–184.
   PubMed Web of Science ®Google Scholar
• Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893–903.
   PubMed Web of Science ®Google Scholar
• Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–234.
   PubMed Web of Science ®Google Scholar
• Lefaucheur J-P, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014–2018). Clin Neurophysiol. 2020;131(2):474–528.
   PubMed Web of Science ®Google Scholar
• Freeman MP. Relapse prevention after recovery in patients with persistent major depressive disorder-an active pursuit. JAMA Psychiatry. 2020;77(3):231–232.
   PubMed Web of Science ®Google Scholar